{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:08:30Z","timestamp":1784977710267,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.clml.2012.09.018","type":"journal-article","created":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T23:46:13Z","timestamp":1351813573000},"page":"287-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Long-Term Follow-Up of Patients With Hypereosinophilic Syndrome Treated With Alemtuzumab, an Anti-CD52 Antibody"],"prefix":"10.1016","volume":"13","author":[{"given":"Paolo","family":"Strati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.09.018_bib1","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jaci.2006.02.042","article-title":"Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report","volume":"117","author":"Klion","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2012.09.018_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaci.2010.03.042","article-title":"Refining the definition of hypereosinophilic syndrome","volume":"126","author":"Simon","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2012.09.018_bib3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ajh.22062","article-title":"World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management","volume":"86","author":"Gotlib","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2012.09.018_bib4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.seminhematol.2012.01.008","article-title":"Eosinophilic myeloid disorders","volume":"49","author":"Noel","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2012.09.018_bib5","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2012.09.018_bib6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.09.018_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.iac.2007.07.002","article-title":"Lymphocytic variant hypereosinophilic syndromes","volume":"27","author":"Roufosse","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.clml.2012.09.018_bib8","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ajh.23193","article-title":"Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation","volume":"87","author":"Helbig","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2012.09.018_bib9","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2012.09.018_bib10","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2006.06038.x","article-title":"Eosinophilia: secondary, clonal and idiopathic","volume":"133","author":"Tefferi","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2012.09.018_bib11","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/cncr.22920","article-title":"A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia","volume":"110","author":"Kalac","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2012.09.018_bib12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/j.seminhematol.2012.01.001","article-title":"Treatment of hypereosinophilic syndromes: the first 100 years","volume":"49","author":"Butterfield","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2012.09.018_bib13","first-page":"304","article-title":"Novel therapies for hypereosinophilic syndromes","volume":"68","author":"Antoniu","year":"2010","journal-title":"Neth J Med"},{"key":"10.1016\/j.clml.2012.09.018_bib14","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood.V88.12.4684.bloodjournal88124684","article-title":"Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils","volume":"88","author":"Elsner","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.018_bib15","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2009-02-203075","article-title":"Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab","volume":"114","author":"Ambrose","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.018_bib16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2004.05206.x","article-title":"Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report","volume":"127","author":"Pitini","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2012.09.018_bib17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1046\/j.1365-2141.2003.04801.x","article-title":"Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome","volume":"124","author":"Sefcick","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2012.09.018_bib18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/1078-0432.CCR-08-1302","article-title":"Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia","volume":"15","author":"Verstovsek","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:03Z","timestamp":1761870243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012002029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S2152265012002029"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.09.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Follow-Up of Patients With Hypereosinophilic Syndrome Treated With Alemtuzumab, an Anti-CD52 Antibody","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}